Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors founded on Medtech developed by Kole Roybal and Alex Marson at the University of California, San Francisco, today announced the close of a $220 million Series B financing round.
